Rockies Chapter Meeting Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit: ACC Rockies Chapter Meeting 2025

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • BETTER-BP, GOFRESH & Healthy Family: Fresh Ideas For BP Control
    With high blood pressure (BP) continuing to be a global challenge, effective management must remain a global priority. The results from three late-breaking studies presented at AHA 2025 are shedding light on diverse behavioral, nutritional and family-centered strategies that may help inform larger-scale models that can be implemented worldwide.
  • DECAF: Does One Cup of Coffee a Day Keep AFib Away?
    Patients with atrial fibrillation (AFib) who drank an average of one cup of coffee a day following successful cardioversion had fewer recurrences of AFib or atrial flutter compared with those who abstained from coffee, based on findings from the DECAF trial presented at AHA 2025 and simultaneously published in JAMA.
  • DARE-AF and META-AF: Mixed Outcomes For Drug Strategies Following AFib Ablation
    Two new studies presented at AHA 2025 shed light on post-ablation strategies for atrial fibrillation (AFib). The DARE-AF trial found that a three-month course of dapagliflozin failed to prevent early AFib recurrence in patients without current indications for SGLT2 inhibitors. In contrast, the META-AF study reported that adding metformin to standard care reduced AFib episodes […]
  • TOP: Does Liberal Transfusion Post Surgery Improve Outcomes in Patients at High CV Risk?
    A liberal transfusion strategy following major vascular or general surgery did not significantly improve outcomes at 90 days post procedure in patients at high risk of a cardiac event when compared to a restrictive strategy, according to findings from the TOP trial presented at AHA 2025 and simultaneously published in JAMA.
  • New Trials Redefine Antithrombotic and Stroke Prevention Strategies in AFib
    Four major studies presented at AHA 2025 are reshaping strategies for managing atrial fibrillation (AFib) in complex clinical scenarios. OCEAN addresses whether ongoing anticoagulation is necessary after successful catheter ablation, offering fresh insights into stroke prevention and bleeding risk. ADAPT AF-DES and OPTIMA-AF explore optimal antithrombotic approaches after PCI, while CLOSURE-AF evaluates left atrial appendage […]